Thermo Fisher Scientific NYSE: TMO expects growth to strengthen in 2027 as biotechnology spending improves and academic research activity stabilizes, Chairman and CEO Marc Casper said during a UBS CEO Call Series discussion.
Casper said the company expects to grow about 4% in 2026, with growth of approximately 5% in the second half. He expects 2027 growth to remain within the company’s previously communicated 3% to 6% organic growth range but improve from this year. Thermo Fisher plans to provide guidance in early February.
The CEO also pointed to the company’s 2028 objective of 7% growth, saying potential benefits from U.S. manufacturing reshoring, artificial intelligence and China could support its outlook. “We’re not capped at all,” he said of the longer-term objective.
Biotech Recovery and Research Funding
Casper said Thermo Fisher’s pharma and biotech business grew at a high-single-digit rate in the third quarter. The industry is recovering rather than operating at a peak, he said, with improved biotech funding giving customers more confidence to advance projects through development.
Biotech spending remains concentrated in later-stage development, but Casper said he expects early research spending to increase as companies refill their pipelines. Thermo Fisher is beginning to see increased demand for basic lab supplies through its Fisher Scientific channel, he said.
Academic and government revenue was flat in the third quarter, and the company expects a slight decline for the full year. Casper said he anticipates the market returning to low-single-digit growth over the next couple of years, supported by U.S. stabilization and an improving outlook in China.
Asked about the U.S. midterm elections, Casper described the potential effect as “constructive and slightly positive.” He said uncertainty, rather than funding levels themselves, had been a major headwind to academic spending and that a split government could reduce some of that uncertainty. He expects the U.S. academic market to return to growth in 2027.
China and Business Performance
China, which Casper said represents about 7.5% of Thermo Fisher’s revenue, delivered low-double-digit growth in the third quarter. He attributed the improvement to strong demand from pharma and biotech customers and semiconductor manufacturers using the company’s electron microscopes.
While China could provide upside to the company’s outlook, Casper cautioned against treating one or two strong quarters as a lasting trend. Thermo Fisher’s existing framework assumes China will be a slight drag on average company growth.
In Life Sciences Solutions, Casper said bioproduction has been growing faster than its expected longer-term rate of high-single-digit to low-double-digit growth, creating tougher comparisons over the next couple of quarters. He expects growth in biosciences and genetic sciences to strengthen as early research markets improve during 2027.
Analytical Instruments grew at a mid-single-digit rate in the third quarter, supported by electron microscopy, chromatography and mass spectrometry. Casper cited strong demand for a new Orbitrap mass spectrometer and for proteomics work, including a collaboration with the Mayo Clinic through a new company called PreCure.
Pharma Services and AI
Casper said pharma services posted very strong third-quarter growth, partly because some work and production campaigns were completed sooner than expected in the fourth quarter. The company has won contracts to manufacture medicines in the U.S. as customers pursue reshoring, he added.
Clinical research is performing well, with new authorizations exceeding revenue, Casper said. He expects the business to progress toward the high end of its long-term mid-single-digit to high-single-digit growth range. The integration of Clario, acquired roughly seven to eight months before the discussion, is off to a good start, he said.
On AI, Casper said pharma and biotech customers are investing in the technology across research and development. Thermo Fisher is applying it to areas including autonomous laboratories and clinical trials, with the aim of helping customers improve pipelines and returns on R&D spending.
About Thermo Fisher Scientific (NYSE:TMO)
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.